A Global Leader in Innovative Animal Models and CRO Solutions
Founded in 2006, Cyagen is a global provider of genetically modified rodent models and advanced CRO solutions for biomedical research and drug development. With more than 900 employees and multiple research facilities covering 40,000 m², we serve researchers in more than 100 countries and support over 13,000 peer-reviewed publications – including in Cell, Nature, and Science.
Headquartered in Santa Clara, California, Cyagen also operates subsidiaries in Japan and China, along with major R&D and production centers in Guangzhou, Suzhou, and Gu'an (China). Leveraging its robust foundation in cell and animal model generation alongside powerful AI-driven discovery platforms, Cyagen offers scalable, reliable, and expert-backed one-stop solutions for accelerating both basic research and preclinical drug development.
To further advance translational research, Cyagen has developed several proprietary platforms:
HUGO-GT™ is a portfolio of genomic sequence humanized mouse models for translational research and drug discovery.
RDDC (Rare Disease Data Center) integrates genetic and disease databases, animal model resources with AI tools to benefit global biomedical research community.
HUGO-Ab™ provides next-generation fully human antibody mouse platforms for efficient therapeutic antibody discovery.
Abseek™ is our AI-powered platform for antibody screening, engineering, and design – streamlining antibody discovery from ideas to IND.
These innovations underscore our commitment to making research more efficient, accurate, and impactful.
Who We Are
Vision & Mission
At Cyagen, our vision is to advance global life science with exceptional models and services. Our mission is to create infinite possibilities for biomedical research by providing reliable tools, scalable technologies, and expert guidance — because at our core, we help you discover life.
Our Team
Our interdisciplinary team includes industry-leading experts in basic science bioinformatics, AI engineers– delivering trusted models and platforms for preclinical validation across all major therapeutic areas.
Lance Han
Founder & President
At Cyagen, we believe in making world-class science more accessible. Through continuous innovation and customer-centered service, we empower researchers to translate ideas into impactful therapies.
Reza Rezaei, PhD
Chief Executive Officer
Our comprehensive model services cover every stage of preclinical research – from design and development to drug screening and efficacy evaluation. We partner with clients to accelerate their scientific breakthroughs.
Check Out The Latest
YIMA and ZIP Solutions Announce Strategic Co-Marketing Agreement for Gene Therapy
June 12, 2025
View Details
HistoWiz and Cyagen Collaborate to Streamline Histopathology for Academic and Preclinical Mouse and Rat Model Research
June 10, 2025
View Details
Cyagen and Landau Strengthen Cooperation to Accelerate the Research and Development of AI-designed AAV Gene Therapy Vectors
June 05, 2025
View Details
Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery
June 03, 2025
View Details